Mike Zanoni News Today : Breaking News, Live Updates & Top Stories | Vimarsana

4D Molecular Therapeutics (FDMT) Reports Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-710

4D Molecular Therapeutics (FDMT) Reports Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-710
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesMike zanoniJenniferl taylor cousarKatherine smithevoke canaleAdult cystic fibrosis programCf foundationCystic fibrosis foundation therapeutics development centerD molecular therapeutics incNational jewish healthInvestor relations corporate affairsMolecular therapeuticsNorth american cystic fibrosis conferencePresentation detailsClinical trialsEvaluate nucleotide basedLead principal investigator

4D Molecular Therapeutics (FDMT) Appoints Noriyuki Kasahara to its Board, Promotes Fred Kamal to COO and President

4D Molecular Therapeutics (FDMT) Appoints Noriyuki Kasahara to its Board, Promotes Fred Kamal to COO and President
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesFred kamalMike zanoniJohn milliganDavid kirnAlveral kanKatherine smithevoke canaleExchange commissionInternational society for cellBrain tumor centerUniversity of california san franciscoInvestor relations corporate affairsD molecular therapeutics incMolecular therapeuticsChief operating officerExecutive chairman

4D Molecular Therapeutics Reports Full Year 2021 Financial Results and Operational Highlights

Provided clinical data updates on three programs, including first clinical data on 4D-310 for Fabry disease and 4D-125 and 4D-110 for inherited retinal dystrophies, each demonstrating preliminary. | March 28, 2022

United statesIngrid mezoMike zanoniDavid kirnExchange commissionCanale communicationsDrug administrationD molecular therapeutics incGlobenewswire incMolecular therapeuticsTherapeutic vector evolutionChief executive officerNew drugMarketable securitiesPrivate securities litigation reform actMolecular therapeutic

4D Molecular Therapeutics Inc (FDMT) Reports Interim Results from 4D-310 Phase 1/2 Trial

4D Molecular Therapeutics Inc (FDMT) Reports Interim Results from 4D-310 Phase 1/2 Trial
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesMike zanoniJerry vockleyRaphael schiffmannCarolyne zimmermannExchange commissionEuropean unionUniversity of pittsburgh school medicineSecurities exchangeD molecular therapeutics incWall streetMolecular therapeuticsSenior vice presidentTherapeutic area headLysosomal storage diseasesGenomic medicine

4D Molecular Therapeutics Announces Pricing of Public

EMERYVILLE, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing.

New yorkUnited statesMike zanoniCarolyne zimmermannD molecular therapeutics incExchange commissionProspectus departmentSecurities exchangeGoldman sachs coSyndicate departmentEvercore groupMolecular therapeuticsGoldman sachsEquity capital marketsTherapeutic vector evolutionSecurities act